Comparative Evaluation of Seven Tigecycline Susceptibility Testing Methods for Carbapenem-Resistant Enterobacteriaceae

References

• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz83031724043
   PubMed Web of Science ®Google Scholar
• CDC. Diseases and organisms in healthcare settings. Available from: https://www.cdc.gov/hai/organisms/organisms.html. Accessed 107, 2019.
   Google Scholar
• Van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020;20(6):731–741. doi:10.1016/S1473-3099(19)30755-832151332
   PubMed Web of Science ®Google Scholar
• Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19(6):601–610. doi:10.1016/S1473-3099(18)30792-831047852
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-128442293
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine. 2016;95:e3126. doi:10.1097/MD.000000000000312626986165
   PubMed Web of Science ®Google Scholar
• He T, Wang R, Liu D, et al. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol. 2019;4(9):1450–1456. doi:10.1038/s41564-019-0445-231133751
   PubMed Web of Science ®Google Scholar
• Deng M, Zhu MH, Li JJ, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother. 2014;58(1):297–303. doi:10.1128/AAC.01727-1324165187
   PubMed Web of Science ®Google Scholar
• Marchaim D, Pogue JM, Tzuman O, et al. Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method. J Clin Microbiol. 2014;52(5):1617–1621. doi:10.1128/JCM.00001-1424599978
   PubMed Web of Science ®Google Scholar
• Yin DD, Guo Y, Li M, et al. Performance of VITEK 2, E-test, Kirby–Bauer disk diffusion, and modified Kirby–Bauer disk diffusion compared to reference broth microdilution for testing tigecycline susceptibility of carbapenem-resistant K. pneumoniae and A. baumannii in a multicenter study in China. Eur J Clin Microbiol Infect Dis. 2021:1–6. doi:10.1007/s10096-020-04123-z33037944
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). The Performance stands for antimicrobial susceptibility testing, M100–S29. 2019.
   Google Scholar
• Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M07–11th edition, Melvin P. Weinstein, MD: CLSI; 2018.
   Google Scholar
• Clinical Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests, M02–13th edition, Melvin P. Weinstein, MD: CLSI; 2018.
   Google Scholar
• Clinical Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters, M23–5th edition Matthew A Wikler, MD, MBA, FIDSA. CLSI; 2018.
   Google Scholar
• US Food and Drug Administration. FDA-Identified Interpretive Criteria for Tigecycline-Injection products; 2019.  Available from: https://www.fda.gov/drugs/development-resources/tigecycline-injection-products. Accessed 330, 2021.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Verification of commercial microbial identification and antimicrobial susceptibility testing systems M52–1st Edition. 2015.
   Google Scholar
• Torrico M, Gonzalez N, Gimenez MJ, et al. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC. J Clin Microbiol. 2010;48(6):2243–2246. doi:10.1128/JCM.00119-1020351208
   PubMed Web of Science ®Google Scholar
• Özkök S, Togan T, Yesilkaya A, et al. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution. Chemotherapy. 2014;60(3):151–156. doi:10.1159/00037544025791941
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao C, Chen H, et al. Comparative evaluation of tigecycline susceptibility testing methods for Acinetobacter baumannii and Enterobacteriaceae. J Glob Antimicrob Resist. 2015;3(2):75–79. doi:10.1016/j.jgar.2015.02.00427873673
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Altouvas G, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol. 2012;50(11):3747–3750. doi:10.1128/JCM.02037-1222933593
   PubMed Web of Science ®Google Scholar
• Casal M, Rodriguez F, Johnson B, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother. 2009;64(1):69–72. doi:10.1093/jac/dkp16919451133
   PubMed Web of Science ®Google Scholar
• Lat A, Clock SA, Wu F, et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol. 2011;49(5):1795–1798. doi:10.1128/JCM.02534-1021367993
   PubMed Web of Science ®Google Scholar
• Huang TD, Berhin C, Bogaerts P, et al. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline. J Antimicrob Chemother. 2012;67(11):2696–2699. doi:10.1093/jac/dks28822833638
   PubMed Web of Science ®Google Scholar
• Idelevich EA, Freeborn DA, Seifert H, et al. Comparison of tigecycline susceptibility testing methods for multidrug-resistant, Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2018;91:360–362.29778562
   PubMed Web of Science ®Google Scholar
• Idelevich EA, Büsing M, Mischnik A, et al. False non-susceptible results of tigecycline susceptibility testing against Enterobacteriaceae by an automated system: a multicentre study. J Med Microbiol. 2016;65(8):877–881. doi:10.1099/jmm.0.00028127188162
   PubMed Web of Science ®Google Scholar